Gilead Sciences, Inc. (NASDAQ:GILD) received a $77.00 price objective from equities research analysts at Mizuho in a research report issued on Sunday, October 29th. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Mizuho’s target price would suggest a potential upside of 8.22% from the company’s current price.
Several other research firms have also issued reports on GILD. ValuEngine upgraded Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research report on Thursday, September 7th. Zacks Investment Research cut Gilead Sciences from a “buy” rating to a “hold” rating in a report on Monday, September 11th. TheStreet upgraded Gilead Sciences from a “c+” rating to a “b-” rating in a report on Thursday, September 7th. Vetr cut Gilead Sciences from a “buy” rating to a “hold” rating and set a $86.44 price objective on the stock. in a report on Monday, September 4th. Finally, Morgan Stanley reiterated an “equal weight” rating and set a $83.00 price objective (up previously from $77.00) on shares of Gilead Sciences in a report on Friday, October 6th. One analyst has rated the stock with a sell rating, twelve have assigned a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the company. Gilead Sciences currently has an average rating of “Buy” and a consensus target price of $84.87.
Shares of Gilead Sciences (GILD) opened at $71.15 on Friday. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $92,920.00, a price-to-earnings ratio of 7.60, a PEG ratio of -1.22 and a beta of 1.13. Gilead Sciences has a 12 month low of $63.76 and a 12 month high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, topping the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s revenue was down 13.2% on a year-over-year basis. During the same period last year, the company earned $2.75 earnings per share. sell-side analysts predict that Gilead Sciences will post 8.53 EPS for the current year.
In other news, EVP Gregg H. Alton sold 50,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The stock was sold at an average price of $79.00, for a total value of $3,950,000.00. Following the transaction, the executive vice president now owns 113,237 shares in the company, valued at $8,945,723. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP James R. Meyers sold 60,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $83.19, for a total value of $4,991,400.00. Following the completion of the transaction, the executive vice president now owns 62,715 shares in the company, valued at approximately $5,217,260.85. The disclosure for this sale can be found here. In the last quarter, insiders sold 446,819 shares of company stock worth $36,269,486. Corporate insiders own 1.30% of the company’s stock.
A number of institutional investors have recently modified their holdings of GILD. Waldron LP increased its position in Gilead Sciences by 20.4% in the first quarter. Waldron LP now owns 10,360 shares of the biopharmaceutical company’s stock worth $711,000 after buying an additional 1,752 shares during the last quarter. Usca Ria LLC increased its position in Gilead Sciences by 203.3% in the first quarter. Usca Ria LLC now owns 57,533 shares of the biopharmaceutical company’s stock worth $3,908,000 after buying an additional 38,565 shares during the last quarter. Stoneridge Investment Partners LLC purchased a new stake in Gilead Sciences in the first quarter worth $4,813,000. Sequoia Financial Advisors LLC increased its position in Gilead Sciences by 10.4% in the first quarter. Sequoia Financial Advisors LLC now owns 80,084 shares of the biopharmaceutical company’s stock worth $5,439,000 after buying an additional 7,562 shares during the last quarter. Finally, Blue Fin Capital Inc. increased its position in Gilead Sciences by 0.8% in the first quarter. Blue Fin Capital Inc. now owns 7,213 shares of the biopharmaceutical company’s stock worth $489,000 after buying an additional 55 shares during the last quarter. Institutional investors and hedge funds own 74.62% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.